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Abbreviations: AD, alzheimer´s disease; APP, amyloid 
precursor protein gene; CAA, cerebral amyloid angiopathy; EOAD, 
early onset alzheimer´s disease; LOAD, late onset Alzheimer´s 
disease; PSEN1, presenilin 1 gene; PSEN2, presenilin 2 gene
Introduction
Familial presentation of Alzheimer disease (AD) accounts for 
approximately 5%-10% of all AD cases. Three genes: the amyloid 
precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 
(PSEN2), were reported as associated with an early-onset form of 
the disease (EOAD). Several mutations (130 mutations) have been 
described in PSEN1, 8 in the PSEN2 gene and about 20 in APP 
(available at http://molgen-www.uia.ac.be/ADmutations).1,2 In 
regards APP mutations, many are considered pathogenic, but other 
are polymorphisms or silent mutations. The A713T mutation is 
associated with a variable phenotype. Some carriers exhibit clinical 
and neuropathological features typical of Alzheimer’s disease, 
while others have a more complex presentation, with prominent 
cerebrovascular disease and cerebral amyloid angiopathy (CAA). 
Asymptomatic carriers have also been documented. We described the 
case of a 71-year-old man who presented recurrent lobar hemorrhagic 
strokes (a chronic form of CAA) with suspected inflammatory 
response; this patient was a carrier of a heterozygous APP A713T 
mutation and had family history of EOAD.
Case presentation
A 71-year-old man was assessed in 2016 at the emergency 
department due to alert deterioration caused by dehydration, his past 
medical history was remarkable. He had suffered from recurrent 
lobar hemorrhagic stroke since age 65. 2009 (right frontal), 2013 
(left temporal) (Image 1), leading to an amyloid angiopathy diagnosis 
base on Boston Criteria; during 6 months in 2012 a low dose of oral 
prednisone was administered due to a suspicion of inflammatory 
amyloid angiopathy. After fluid administration the patient recovered 
to his baseline status: a major cognitive deterioration, left hemiparesis 
and severe mix aphasia was observed as sequelae, he was able to walk 
supervised. His relatives reported a gradual cognitive deterioration 
during the past year. 
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Abstract
Aim: To report the case of a patient who suffered from cerebral amyloid angiopathy 
due to an autosomal dominant mutation in the APP gene
Design/Methods: Medical record and neuroimaging revision. DNA extraction from 
the saliva sample. Sanger sequencing of the coding regions of the following: APP 
(NCBI RefSeq NM_000484.3), PSEN1 (NCBI RefSeq NM_000021.3) y PSEN2 
(NCBI RefSeq NM_000447.2)
Clinical case: A male patient of 71-year-old with a past medical history of recurrent 
lobar hemorrhagic strokes leading to major cognitive decline since the age of 65, 
prominent cerebral microangiopathy was present and worsened progressively. 
Patient´s mother had presenile Alzheimer`s disease. The patient developed partial non-
convulsive status epilepticus, no evidence of new strokes (ischemic or hemorrhagic) 
was found. Two weeks after seizures a new MRI unveiled right frontal meningeal 
enhancement. Lumbar puncture and cultures were normal. Inflammatory amyloid 
angiopathy was suspected. A course of IV methylprednisolone was administered 
followed by oral steroids with a slight improvement. The patient died four months 
after due to clinical complications. Post-mortem analysis confirmed a heterozygous 
mutation: c.2137G>A; p.Arg713Thr at exon 17 of the APP gene. 
Conclusion: The A713T mutation has been reported by groups of European researchers 
(British, Spanish and Italian) with variable phenotypes. This would be the first case 
detected in Argentina to our knowledge. It is notable the main manifestation in our 
case was the presence of recurrent hemorrhagic stroke, however, the antecedent of a 
pre-senile AD in a first-degree relative suggested the presence of genetic etiology. This 
mutation may be underdiagnosed. It would be advisable that a complete genogram 
must be performed in patients with cerebral amyloid angiopathy. The detection of 
these cases has implications for genetic counselling.
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Image 1 A) Axial MRI T2 and FLAIR. Right frontal hematoma. Subcortical white matter lesion (2009). B) CT Scan. Axial. Left temporal hematoma. (2013)
Familiar antecedent of EOAD (patient’s mother) without clinical 
cerebrovascular disease was reported by relatives. One older brother 
and two siblings were healthy. Four months after the initial assessment 
a tapering of valproic acid was initiated, because of he had none record 
of seizures and was receiving a suboptimal dosing of 500 mg/day. The 
patient developed a status epilepticus, starting as partial left motor 
clonic movements, followed by a generalized tonic-clonic seizure. 
After IV Levetiracetam´s infusion clinical seizures stopped but EEG 
evidenced frequent right frontal electrographic seizures. Lacosamide 
200 mg oral charge finally stopped seizures.
Despite of EEG normalization, clinical status did not improve. 
Lumbar puncture was normal, Brain CT and MRI showed old ischemic 
and hemorrhagic sequelae. After 2 weeks mental status was below 
his previous baseline, hyperactive and hypoactive delirium persisted 
despite antipsychotic medication. A new contrast-MRI showed 
right frontal pachymeningeal, leptomeningeal enhancement, and 
gyral edema in FLAIR/T2 sequences, the same was retrospectively 
observed in the first non-contrasted MRI (Image 2). Despite 
atypical neuroimaging and age, inflammatory amyloid angiopathy 
was suspected due to meningeal enhancement, new seizures onset 
and continuous cognitive deterioration during the months before 
hospitalization. As a differential diagnosis post seizures edema was 
proposed, but none DWI restriction was observed in the first and 
second MRI within 2 weeks. Finally, 3 g of methylprednisolone was 
administered followed by oral prednisone. A slight improvement was 
observed (the patient recovered from prostration and start walking 
again, but persisted markedly confused). 3 months later the patient 
died from pneumonia. 
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Image 2 Axial FLAIR and AXIAL T1 gadolinium enhanced, right frontal meningeal.
The familiar antecedents rise suspicion of an amyloid precursor 
protein (APP) mutation in the kindred and after informed consent 
PSEN1, PSEN1 and APP gene analysis was performed using Sanger 
sequencing method. ADN was extracted from a saliva sample. Result 
from a heterozygous mutation c.2137G>A; p.Arg713Thr in 17 exon 
of APP gene was received post mortem (Image 3). 
Image 3 Genetic testing.
Discussion
The APP A713T mutation has been reported with dominant 
inheritance and in heterozygosis, associated with familial AD with 
both early and late onset and cerebrovascular lesions.3 Unlike PSEN1 
and PSEN2, causative APP mutations are clustered into just 2 exons 
(16 and 17), both of which are less than 500 base pairs and therefore 
amenable to screening via Sanger sequencing.4
 The first report from 1992, described a sample of 130 EOAD 
patients that were screened for this mutation, finding 1 case of a 
64-year-old female. 5 relatives were asymptomatic carriers, (2 of them 
older than 62 and one of 88-year-old). No stroke-like manifestation 
was reported. 123 non-affected individuals were screened too, 
with negative results.5 In 2004 another group3 from Italy, described 
that six affected subjects were identified in a family; the age at 
onset ranged from 52 to 68 and the age at death from 57 to 73, in 
the similar age of our patient. Two prob and developed early onset 
dementia, stroke like episodes, with white matter lesions without 
hemorrhages or hemosiderosis. Post mortem and biopsy pathological 
study showed AD pathology, amyloid angiopathy and infarcts in the 
territory of the long penetrating arteries. The junction between the 
cortex and the subcortical white matter and the periventricular white 
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matter were mostly involved. Our case displayed a combination of 
both haemorragic strokes and periventricular/white matter ischemic 
lesions. Authors considered that penetrance of A713T could not be 
determined in that study due to the young age of many carriers. In 
2004 another group Armstrong et al. 6 described a case of A713T 
mutation´s carrier of 56 year old with 7 years of cognitive decline 
which leads to severe dementia and prostration; postmortem analysis 
showed diffuse atrophy and AD pathology, CAA restricted only to 
meningeal and parenchymal vessels.
As in our case it seems that in the same kindred a variety of 
clinical manifestations are possible, but the most elusive could be the 
presentation of late onset AD with brain microangiopathy as described 
by Bernardi et al.7 in 2009.The researchers found A713T mutation in 
three of 59 (5%) unrelated patients, which age of onset was between 
72–82 years.7 However, despite de prevalence in their study, at the same 
time, researchers suggest that probably this mutation is extremely rare 
in worldwide population, since all the cases had ancestors in a limited 
area of Italy. A later study from England, based on the analysis of 451 
EOAD, detected only 2 carriers of A713T mutation.4 
The larger description of a kindred was performed by Conidi et 
al.8 over a 6 generations, including homozygotic and heterozygotic 
carriers. They found no differences in clinical phenotype in those 
patients, which suffered from late onset dementia with cerebral 
microangiopathy. According the mentioned articles A713T is present 
mostly in Europe. Argentina has received a massive European 
immigration during XX century, mostly from Italy and Spain, it could 
be possible that our patient had an European ancestor.
Finally, in this paper we highlight the prominence of recurrent 
hemorrhagic strokes (clinical amyloid angiopathy), and cerebral 
microangiopathy at a relative young age over the typical Alzheimer´s 
disease phenotype, reported in previous studies. The rapid decline 
during the last year of disease with seizures, meningeal enhancement 
and gyral swelling close to an old stroke, suggested a SNC 
inflammatory response. 
This report has many limitations; first, no medical record related 
to patient´s mother was available, the information was based on 
relative´s information, second, neither a brain biopsy or post-
mortem anatomopathological analysis was performed, it would be 
relevant to confirm the presence of AD pathology and the theoretical 
inflammatory response. Finally, the relatives decline to receive any 
information related to genetic counselling, closing the possibility to 
analyze for asymptomatic carriers too. The A713T mutation has been 
reported by groups of European researchers. They described variable 
phenotypes (EOAD, LOAD with or without cerebral microangiopathy 
due to CAA). This would be the first case detected in Argentina to our 
knowledge. It is notable that the main manifestation in our case was 
the presence of recurrent hemorrhagic stroke, however, the antecedent 
of pre-senile AD in a first-degree relative suggested the presence of 
genetic etiology. This mutation may be underdiagnosed.
It would be advisable that a complete genogram must to be 
performed in patients with cerebral amyloid angiopathy and prominent 
white matter ischemic lesions.
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